

# Produktinformation



Forschungsprodukte & Biochemikalien
Zellkultur & Verbrauchsmaterial
Diagnostik & molekulare Diagnostik
Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart siehe unsere Liefer- und Versandbedingungen

# Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

## SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien T. +43(0)1 489 3961-0 F. +43(0)1 489 3961-7 <u>mail@szabo-scandic.com</u> www.szabo-scandic.com



# Data Sheet Papain-like Protease (SARS-CoV-2) Assay Kit: Protease Activity Catalog #79995 Size: 96 reactions

**BACKGROUND:** Coronaviruses (CoVs) primarily cause multiple respiratory and intestinal infections in humans and animals. Papain-Like Protease (PLPro), also known as PLP, plays an essential role in polypeptide processing during virus replication. PLProis also proposed to be a key enzyme in the sustained pathogenesis of SARS-CoV-2. PLP acts as a deubiquitinase that removes ubiquitin and ISG15 from host-cell proteins to aid coronaviruses in their evasion of the host innate antiviral immune responses. As a result, PLPro is an important potential target for antiviral drugs that may inhibit viral replication and simultaneously weaken dysregulation of signaling cascades in infected cells that may lead to cell death in surrounding, uninfected cells. PLPro inhibitors that can block viral replication are promising potential drug candidates that could be used to treat patients suffering with the COVID-19 coronavirus infection.

**DESCRIPTION:** The *Papain-like Protease Assay Kit: Protease Activity* is designed to measure Papain-like Protease activity for screening and profiling applications, in a homogeneous assay with no time-consuming washing steps. The kit comes in a convenient 96-well format, with purified Papain-like Protease, fluorogenic substrate, and PLPro assay buffer for 100 enzyme reactions. PLPro inhibitor GRL0617 is also included as a positive control.

COMI CNENTS:						
Catalog #	Component	Amount	Storage			
100758	Recombinant Papain-like Protease, PLPro	5 µg	-80°C	Avoid		
79997	PLPro Substrate (5 mM)	50 µl	-80°C	freeze/		
	PLPro Assay Buffer	25 ml	-20°C	thaw		
	10 mM GRL0617 (10 μM)	20 µl	-80°C	cycles!		
	Dithiothreitol (DTT; 0.5 M)	200 µl	-20°C			
79685	Black, low binding microtiter plate with	1	Room			
	plate sealer	I	Temperature			

### COMPONENTS:

**APPLICATIONS:** Great for studying enzyme kinetics and HTS applications.

**STABILITY:** At least six months from date of receipt when stored as directed.

#### **REFERENCE(S)**:

Weglarz-Tomczak, E. *et al.*, 2020. https://doi.org/10.1101/2020.05.17.100768. OUR PRODUCTS ARE FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

To place your order, please contact us by Phone **1.858.202.1401**, Fax **1.858.481.8694** Or you can Email us at: <u>info@bpsbioscience.com</u> Please visit our website at: <u>www.bpsbioscience.com</u>



#### MATERIALS OR INSTRUMENTS REQUIRED BUT NOT SUPPLIED:

Fluorescent microplate reader capable of reading \lambda exc/\lambda em=360 nm/460 nm

#### ASSAY PROTOCOL:

#### All samples and controls should be tested in duplicate.

- Add 0.5 M DTT to PLPro Assay Buffer so final DTT concentration is 1 mM. For example, add 10 μl of 0.5 M DTT to 5 ml assay buffer. (DTT should be added just before use. Prepare only enough DTT-containing buffer as required for the assay. Store the remaining assay buffer at -20°C).
- 2) Thaw PLPro on ice. Upon first thaw, briefly spin tube containing enzyme to recover the full content of the tube. Aliquot PLPro into single use aliquots. Store remaining undiluted enzyme in aliquots at -80°C. Note: PLPro enzyme is sensitive to freeze/thaw cycles. Do not re-use diluted enzyme.
- Dilute PLPro in PLPro Assay buffer (with 1 mM DTT) at 0.3-0.5 ng/µl (9-15 ng per reaction).

Component	Positive Control	Test Sample	Inhibitor Control	Blank
PLPro (0.3-0.5 ng/µl)	30 µl	30 µl	30 µl	_
Assay Buffer (with DTT)	-	-	-	30 µl
GRL0617 (500 µM)	-	-	10 µl	
Test Inhibitor	-	10 µl	-	-
Inhibitor Buffer (no inhibitor)	10 µl	-	-	10 µl
Substrate solution	10 µl	10 µl	10 µl	10 µl
Total	50 µl	50 µl		50 µl

4) Add 30 µl diluted **PLPro** enzyme solution to wells designated as "Positive Control", "Inhibitor Control" and "Test Sample". Add 30 µl **Assay buffer** (with 1 mM DTT) to the "Blank" wells.

- 5) Add 190 μl of **PLPro Assay buffer** (with 1 mM DTT) to 10 μl **GRL0617** to obtain a 500 μM solution. Add 10 μl **GRL0617** (500 μM) to the wells labeled "Inhibitor Control". Do not keep buffer-containing solution more than one day.
- 6) Prepare the inhibitor solution.

The final concentration of DMSO in the assay should not exceed 1%. If the inhibitor compound is dissolved in DMSO, make a 100-fold higher concentration of the compound than the highest concentration you want to test in DMSO. Then make a 20-fold dilution in PLPro assay buffer with 1 mM DTT.(At this step the compound concentration is 5-fold higher than the final concentration.)

OUR PRODUCTS ARE FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

To place your order, please contact us by Phone **1.858.202.1401**, Fax **1.858.481.8694** Or you can Email us at: <u>info@bpsbioscience.com</u> Please visit our website at: <u>www.bpsbioscience.com</u>




If the inhibitor compound is dissolved in water, make a solution of the compound 5-fold higher than the final concentration in PLPro assay buffer (with 1 mM DTT).

- Add 10 µl inhibitor to each well designated "Test Sample". Add 10 µl 1X PLPro assay buffer with 1 mM DTT or 5% DMSO (depending which inhibitor solution is used) to "Blank" and "Positive Control" wells.
- 8) Preincubate enzyme with the inhibitor for 30 minutes at 37°C.
- Dilute 5 mM PLPro substrate 1:20 in assay buffer with DTT, to make a 250 μM solution. Dilute only enough as is required for the assay.
- 10) Start reaction by adding 10  $\mu$ l of the substrate solution to each well (Final concentration of the **PLPro substrate** in a 50  $\mu$ l reaction is 50  $\mu$ M).
- 11) Incubate at 37°C for 45-60 minutes. Measure the fluorescence intensity in a microtiter plate-reading fluorimeter capable of excitation at a wavelength 360 nm and detection of emission at a wavelength 460 nm. The fluorescence intensity can also be measured kinetically. "Blank" value is subtracted from all other values.

#### **EXAMPLE OF ASSAY RESULTS:**





Inhibition of PLPro Protease enzyme activity by GRL0617, measured using the *Papainlike Protease Assay Kit: Protease Activity (BPS Bioscience #79995).* Fluorescence intensity was measured using a Tecan fluorescent microplate reader. *Data shown is lotspecific. For lot-specific information, please contact BPS Bioscience, Inc. at info@bpsbioscience.com* 

OUR PRODUCTS ARE FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

To place your order, please contact us by Phone **1.858.202.1401**, Fax **1.858.481.8694** Or you can Email us at: <u>info@bpsbioscience.com</u> Please visit our website at: <u>www.bpsbioscience.com</u>



## **RELATED PRODUCTS**

Product	<u>Cat. #</u>	<u>Size</u>
Recombinant 3CL Protease, MBP-tag	100707-1	100 µg
PLPro, His-tag (SARS-CoV-2)	100735	20 µg/50 µg
PLPro, His-tag (SARS-CoV)	81091	25 µg
SARS-CoV-2 Spike:ACE2 Inhibitor Screening Kit	79931	96 reactions
ACE2:SARS-CoV-2 Spike Inhibitor Screening Kit	79936	96 reactions
ACE2:SARS-CoV-2 Spike S1-Biotin Inhibitor		
Screening Kit	79945	96 reactions
SARS-CoV-2 Spike S1-Biotin:ACE2 TR-FRET Kit	79949	96 reactions
Spike S1, Fc Fusion, Avi-tag (SARS-CoV-2)	100678	100 µg/1 mg
Spike S1, Fc fusion, Avi-tag, Biotin-Labeled	100679	25 µg/50 µg
Spike S1 RBD, His-tag (SARS-CoV-2)	100687	50 µg/100 µg
Spike S1, Fc fusion (SARS-CoV-2)	100688	20 µg/50 µg
Spike S1 RBD, Fc fusion (SARS-CoV-2)	100699	50 µg/100 µg
ACE2 Inhibitor Screening Assay Kit	79923	96 reactions
ACE2, His-tag	11003	20 µg/100 µg
ACE2, His-Avi-Tag, Biotin-labeled HiP™	100665	20 µg/50 µg
ACE2, Fc Fusion (Monkey)	100701	50 µg/1 mg
ACE2, His-tag (Monkey)	100702	50 µg/1 mg

OUR PRODUCTS ARE FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.